Open AccessInsights into cardio-oncology: Polypharmacology of quinazoline-based α1-adrenoceptor antagonists
Author(s) -
Salvatore Patanè
Publication year - 2015
Publication title -
world journal of cardiology
Language(s) - English
Resource type - Journals
ISSN - 1949-8462
DOI - 10.4330/wjc.v7.i5.238
Subject(s) - doxazosin , medicine , quinazoline , terazosin , prazosin , pharmacology , cancer , antagonist , blood pressure , combinatorial chemistry , receptor , chemistry , hyperplasia
New uses of cardiovascular drugs with proven experience are emerging, including for treating cancer. Quinazoline is a compound made up of two fused six member simple aromatic rings, benzene and pyrimidine rings, with several biological effects. Cardiologists first used quinazoline-based α1-adrenoceptor antagonists prazosin, doxazosin, and terazosin; currently available data support their use as safe, well tolerated, and effective add-on therapy in uncontrolled hypertension with additional favourable metabolic effects. Recent findings highlight the anticancer effects of quinazoline-based α1-adrenoceptor antagonists, indicating that they may have a significant role in uncontrolled hypertensive cancer patients without signs of ischemia.